Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and BMS-813160 With or Without GVAX in Locally Advanced Pancreatic Cancer
NCT03767582Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2019
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of BMS-813160, nivolumab, GVAX pancreatic cancer vaccine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03767582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767582.